What are the major opportunities in the Oral Hypoglycemic Agents market? What are the strategies for the Oral Hypoglycemic Agents market?

For detailed insights on the major opportunities and strategies in the Oral Hypoglycemic Agents market, Read More

How does the Oral Hypoglycemic Agents market relate to the overall economy and other similar markets?

For detailed insights on Oral Hypoglycemic Agents's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Oral Hypoglycemic Agents market growth? SWOT analysis of the Oral Hypoglycemic Agents market.

For detailed insights on the key dynamics influencing the Oral Hypoglycemic Agents market growth and SWOT analysis of the Oral Hypoglycemic Agents industry, Read More

Global Oral Hypoglycemic Agents Market Report 2025

Item added to cart!

Published : December 2025

Pages : 200

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Oral Hypoglycemic Agents Global Market Report 2025

Name: Oral Hypoglycemic Agents Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Product Type (Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Immunotherapy), By Administration Route (Oral Tablets, Oral Liquids, Extended-Release Formulations, Combination Therapy Formulations), By Patient Type (Type 2 Diabetes Mellitus Patients, Pre-diabetic Patients, Obese Or Overweight Patients, Patients with Multiple Comorbidities), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Nursing Homes and Long-Term Care Facilities), By End users (Hospitals, Clinics) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Oral Hypoglycemic Agents Market Overview

• Oral Hypoglycemic Agents market size has reached to $57.04 billion in 2024

• Expected to grow to $72.09 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%

• Growth Driver: Rising Prevalence Of Type 2 Diabetes Driving Growth In The Market Due To Increasing Obesity And Demand For Effective Blood Sugar Management

• Market Trend: Development Of Advanced Oral Hypoglycemic Agents Driving Market Growth, With DPP-4 Inhibitors Gaining Traction

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oral Hypoglycemic Agents Market?

Oral hypoglycemic agents (OHAs) are medications taken by mouth to help lower blood glucose (sugar) levels in individuals with type 2 diabetes mellitus. These drugs work through various mechanisms, such as increasing insulin secretion, improving insulin sensitivity, reducing glucose absorption from the gut, or decreasing glucose production by the liver. Oral hypoglycemic agents are typically prescribed when lifestyle modifications such as diet and exercise alone are insufficient to control blood sugar.

The main product types of oral hypoglycemic agents are sulfonylureas, metformin, thiazolidinediones, Alpha-Glucosidase Inhibitors, and immunotherapy. Sulfonylureas refer to a class of oral hypoglycemic agents that stimulate the pancreas to release more insulin by acting on beta cells, thereby helping lower blood glucose levels in individuals with type 2 diabetes. The various routes of administration include oral tablets, oral liquids, extended-release formulations, and combination therapy formulations. The multiple patient types include type 2 diabetes mellitus patients, pre-diabetic patients, obese or overweight patients, and patients with multiple comorbidities and are distributed through several channels such as hospital pharmacies, retail pharmacies, online pharmacies, and nursing homes and long-term care facilities. The different end users include hospitals and clinics.

Oral Hypoglycemic Agents Market Size and growth rate 2025 to 2029: Graph

What Is The Oral Hypoglycemic Agents Market Size 2025 And Growth Rate?

The oral hypoglycemic agents market size has grown strongly in recent years. It will grow from $57.04 billion in 2024 to $59.57 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to the growing prevalence of type 2 diabetes, rising geriatric population, growing awareness of diabetes management, expansion of healthcare access in emerging markets, and the preference for oral over injectable therapies.

What Is The Oral Hypoglycemic Agents Market Growth Forecast?

The oral hypoglycemic agents market size is expected to see strong growth in the next few years. It will grow to $72.09 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to rising demand for combination therapies, supportive government healthcare policies, increasing adoption of telemedicine for diabetes care, rising investment in research and development for diabetes treatments, and rising focus on personalized diabetes treatment. Major trends in the forecast period include the development of novel oral antidiabetics, the development of fixed-dose combinations, technological advancements in drug formulation, a focus on reducing drug side effects, and the integration of digital health tools for glucose monitoring.

The forecast of 4.9% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could disrupt diabetes management by inflating prices of sodium-glucose cotransporter-2 inhibitors anddipeptidyl peptidase-4 inhibitors manufactured in Japan and Switzerland, resulting in compromised glycemic control and higher type 2 diabetes treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Oral Hypoglycemic Agents Market Segmented?

1) By Product Type: Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Immunotherapy

2) By Administration Route: Oral Tablets, Oral Liquids, Extended-Release Formulations, Combination Therapy Formulations

3) By Patient Type: Type 2 Diabetes Mellitus Patients, Pre-diabetic Patients, Obese Or Overweight Patients, Patients with Multiple Comorbidities

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Nursing Homes and Long-Term Care Facilities

5) By End users: Hospitals, Clinics

Subsegments:

1) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide

2) By Metformin: Immediate-Release Metformin, Extended-Release Metformin (XR), Combination Metformin

3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose

5) By Immunotherapy: Teplizumab, Alum-Formulated GAD (GAD-Alum), Diamyd, Anti-CD3 Monoclonal Antibodies

What Is Driving The Oral Hypoglycemic Agents Market? Rising Prevalence Of Type 2 Diabetes Driving Growth In The Market Due To Increasing Obesity And Demand For Effective Blood Sugar Management

The rise in type 2 diabetes prevalence is expected to propel the growth of the oral hypoglycemic agents market going forward. Type 2 diabetes refers to a chronic metabolic disorder characterized by the body’s ineffective use of insulin, leading to elevated blood glucose levels. Type 2 diabetes is rising due to the increasing prevalence of sedentary lifestyles, which significantly reduce physical activity and contribute to obesity and insulin resistance. Oral hypoglycemic agents help manage type 2 diabetes by lowering blood glucose levels through various mechanisms, such as enhancing insulin sensitivity, stimulating insulin secretion, or reducing glucose absorption. For instance, in April 2025, according to the International Diabetes Federation (IDF), a Belgium-based non-profit organization, nearly 589 million adults aged 20–79 are living with diabetes worldwide, and this number is projected to rise significantly to 853 million by 2050. Therefore, the rising incidence of type 2 diabetes drives growth in the oral hypoglycemic agents industry.

Who Are The Major Players In The Global Oral Hypoglycemic Agents Market?

Major companies operating in the oral hypoglycemic agents market are Pfizer Inc., Janssen Global Services LLC, Merck Sharp & Dohme Corp., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceuticals Limited, Eli Lilly and Company, Boehringer Ingelheim Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Laboratoires Servier, Huadong Medicine Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Gan & Lee Pharmaceuticals Co. Ltd., Biocon Limited, Wanbang Biopharmaceuticals Co. Ltd.

What Are The Key Trends Of The Global Oral Hypoglycemic Agents Market? Development Of Advanced Oral Hypoglycemic Agents Driving Market Growth, With DPP-4 Inhibitors Gaining Traction

Major companies operating in the oral hypoglycemic agents market are focusing on developing advanced therapeutic solutions, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, to improve blood sugar control in patients with Type 2 diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are type 2 diabetes medications that boost incretin hormone levels, enabling the body to produce insulin, thereby lowering blood sugar levels. For instance, in June 2022, Gan & Lee Pharmaceuticals Co. Ltd., a China-based pharmaceutical company, received approval for Sitagliptin Phosphate tablets, a self-developed oral hypoglycemic medication designed to manage Type 2 diabetes effectively. This product offers an effective treatment option by inhibiting the DPP-4 enzyme, which helps regulate blood sugar levels. This launch marks Ganlee Pharmaceuticals' entry into the generic drug market, offering a cost-effective alternative for managing type 2 diabetes.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Oral Hypoglycemic Agents Market? Roche’s Acquisition Of Carmot Therapeutics Strengthens Market Position Through Innovation In Obesity And Diabetes Care

In July 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, Roche aims to strengthen its presence in the obesity and diabetes treatment market by expanding its pipeline of advanced incretin-based therapies. Carmot Therapeutics Inc. is a US-based company specializing in developing incretin-based therapies for obesity, diabetes, and related metabolic disorders.

What Is The Regional Outlook For The Global Oral Hypoglycemic Agents Market?

North America was the largest region in the oral hypoglycemic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Oral Hypoglycemic Agents Market?

The oral hypoglycemic agents market consists of sales of DPP-4 inhibitors, alpha-glucosidase inhibitors, biguanides, and thiazolidinediones (TZDs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Oral Hypoglycemic Agents Industry?

The oral hypoglycemic agents market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oral hypoglycemic agents industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Oral Hypoglycemic Agents Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$59.57 billion
Revenue Forecast In 2034	$72.09 billion
Growth Rate	CAGR of 4.9% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The oral hypoglycemic agents market covered in this report is segmented – 1) By Product Type: Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Immunotherapy 2) By Administration Route: Oral Tablets, Oral Liquids, Extended-Release Formulations, Combination Therapy Formulations 3) By Patient Type: Type 2 Diabetes Mellitus Patients, Pre-diabetic Patients, Obese Or Overweight Patients, Patients with Multiple Comorbidities 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Nursing Homes and Long-Term Care Facilities 5) By End users: Hospitals, Clinics Subsegments: 1) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide 2) By Metformin: Immediate-Release Metformin, Extended-Release Metformin (XR), Combination Metformin 3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone 4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose 5) By Immunotherapy: Teplizumab, Alum-Formulated GAD (GAD-Alum), Diamyd, Anti-CD3 Monoclonal Antibodies
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Janssen Global Services LLC, Merck Sharp & Dohme Corp., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceuticals Limited, Eli Lilly and Company, Boehringer Ingelheim Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Laboratoires Servier, Huadong Medicine Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Gan & Lee Pharmaceuticals Co. Ltd., Biocon Limited, Wanbang Biopharmaceuticals Co. Ltd.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Oral Hypoglycemic Agents Market Characteristics

3. Oral Hypoglycemic Agents Market Trends And Strategies

4. Oral Hypoglycemic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Oral Hypoglycemic Agents Growth Analysis And Strategic Analysis Framework

5.1. Global Oral Hypoglycemic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Oral Hypoglycemic Agents Market Growth Rate Analysis

5.4. Global Oral Hypoglycemic Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Oral Hypoglycemic Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Oral Hypoglycemic Agents Total Addressable Market (TAM)

6. Oral Hypoglycemic Agents Market Segmentation

6.1. Global Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Sulfonylureas

Metformin

Thiazolidinediones

Alpha-Glucosidase Inhibitors

Immunotherapy

6.2. Global Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral Tablets

Oral Liquids

Extended-Release Formulations

Combination Therapy Formulations

6.3. Global Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Type 2 Diabetes Mellitus Patients

Pre-Diabetic Patients

Obese Or Overweight Patients

Patients With Multiple Comorbidities

6.4. Global Oral Hypoglycemic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Nursing Homes and Long-Term Care Facilities

6.5. Global Oral Hypoglycemic Agents Market, Segmentation By End users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Clinics

6.6. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Glipizide

Glyburide

Glimepiride

Chlorpropamide

Tolbutamide

6.7. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immediate-Release Metformin

Extended-Release Metformin (XR)

Combination Metformin

6.8. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Thiazolidinediones (TZDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pioglitazone

Rosiglitazone

6.9. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Acarbose

Miglitol

Voglibose

6.10. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Teplizumab

Alum-Formulated GAD (GAD-Alum)

Diamyd

Anti-CD3 Monoclonal Antibodies

7. Oral Hypoglycemic Agents Market Regional And Country Analysis

7.1. Global Oral Hypoglycemic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Oral Hypoglycemic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oral Hypoglycemic Agents Market

8.1. Asia-Pacific Oral Hypoglycemic Agents Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oral Hypoglycemic Agents Market

9.1. China Oral Hypoglycemic Agents Market Overview

9.2. China Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oral Hypoglycemic Agents Market

10.1. India Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oral Hypoglycemic Agents Market

11.1. Japan Oral Hypoglycemic Agents Market Overview

11.2. Japan Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oral Hypoglycemic Agents Market

12.1. Australia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oral Hypoglycemic Agents Market

13.1. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oral Hypoglycemic Agents Market

14.1. South Korea Oral Hypoglycemic Agents Market Overview

14.2. South Korea Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oral Hypoglycemic Agents Market

15.1. Western Europe Oral Hypoglycemic Agents Market Overview

15.2. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oral Hypoglycemic Agents Market

16.1. UK Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oral Hypoglycemic Agents Market

17.1. Germany Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oral Hypoglycemic Agents Market

18.1. France Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oral Hypoglycemic Agents Market

19.1. Italy Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oral Hypoglycemic Agents Market

20.1. Spain Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oral Hypoglycemic Agents Market

21.1. Eastern Europe Oral Hypoglycemic Agents Market Overview

21.2. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oral Hypoglycemic Agents Market

22.1. Russia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oral Hypoglycemic Agents Market

23.1. North America Oral Hypoglycemic Agents Market Overview

23.2. North America Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oral Hypoglycemic Agents Market

24.1. USA Oral Hypoglycemic Agents Market Overview

24.2. USA Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oral Hypoglycemic Agents Market

25.1. Canada Oral Hypoglycemic Agents Market Overview

25.2. Canada Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oral Hypoglycemic Agents Market

26.1. South America Oral Hypoglycemic Agents Market Overview

26.2. South America Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oral Hypoglycemic Agents Market

27.1. Brazil Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oral Hypoglycemic Agents Market

28.1. Middle East Oral Hypoglycemic Agents Market Overview

28.2. Middle East Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oral Hypoglycemic Agents Market

29.1. Africa Oral Hypoglycemic Agents Market Overview

29.2. Africa Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oral Hypoglycemic Agents Market Competitive Landscape And Company Profiles

30.1. Oral Hypoglycemic Agents Market Competitive Landscape

30.2. Oral Hypoglycemic Agents Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Janssen Global Services LLC Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck Sharp & Dohme Corp. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Oral Hypoglycemic Agents Market Other Major And Innovative Companies

31.1. Sanofi S.A.

31.2. AstraZeneca plc

31.3. Novartis AG

31.4. GSK plc

31.5. Takeda Pharmaceuticals Limited

31.6. Eli Lilly and Company

31.7. Boehringer Ingelheim Ltd.

31.8. Novo Nordisk A/S

31.9. Astellas Pharma Inc.

31.10. Laboratoires Servier

31.11. Huadong Medicine Co. Ltd.

31.12. Tonghua Dongbao Pharmaceutical Co. Ltd.

31.13. Gan & Lee Pharmaceuticals Co. Ltd.

31.14. Biocon Limited

31.15. Wanbang Biopharmaceuticals Co. Ltd.

32. Global Oral Hypoglycemic Agents Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oral Hypoglycemic Agents Market

34. Recent Developments In The Oral Hypoglycemic Agents Market

35. Oral Hypoglycemic Agents Market High Potential Countries, Segments and Strategies

35.1 Oral Hypoglycemic Agents Market In 2029 - Countries Offering Most New Opportunities

35.2 Oral Hypoglycemic Agents Market In 2029 - Segments Offering Most New Opportunities

35.3 Oral Hypoglycemic Agents Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Oral Hypoglycemic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Oral Hypoglycemic Agents Market, Segmentation By End users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Thiazolidinediones (TZDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Oral Hypoglycemic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Global Oral Hypoglycemic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: Asia-Pacific, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: China, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: India, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Japan, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Australia, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Indonesia, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: South Korea, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Western Europe, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: UK, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Germany, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: France, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Italy, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Spain, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Eastern Europe, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: Russia, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: North America, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: USA, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Canada, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: South America, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Brazil, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Middle East, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Africa, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 81: Pfizer Inc. Financial Performance

Table 82: Janssen Global Services LLC Financial Performance

Table 83: Merck Sharp & Dohme Corp. Financial Performance

Table 84: Bayer AG Financial Performance

Table 85: Bristol-Myers Squibb Company Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Oral Hypoglycemic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Oral Hypoglycemic Agents Market, Segmentation By End users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Thiazolidinediones (TZDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Oral Hypoglycemic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Global Oral Hypoglycemic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: Asia-Pacific, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: China, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: India, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Japan, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Australia, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Indonesia, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: South Korea, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Western Europe, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: UK, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Germany, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: France, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Italy, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Spain, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Eastern Europe, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: Russia, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: North America, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: USA, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Canada, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: South America, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Brazil, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Middle East, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Africa, Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 81: Pfizer Inc. Financial Performance

Figure 82: Janssen Global Services LLC Financial Performance

Figure 83: Merck Sharp & Dohme Corp. Financial Performance

Figure 84: Bayer AG Financial Performance

Figure 85: Bristol-Myers Squibb Company Financial Performance

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Oral Solid Dosage Pharmaceutical Formulation Global Market Report 2025 – By Dosage Form (Tablets, Capsules, Powders And Granules, Lozenges And Pastilles, Gummies), By Mechanism (Controlled-Release, Immediate-Release, Del...

Antidiabetics Global Market Report 2025 – By Drug Class (Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Other Drug Classes,), By Diabetes Type (Type 1, Type 2), By Patient Population (Antidiabetic...

Dental Sleep Medicine Global Market Report 2025 – By Type (Diagnostic, Treatment), By Age Group ( Pediatric, Adult, Geriatric), By End User (Hospitals, Sleep Laboratories, Home, Other End Users) – Impact of Tariff and Tr...

Oral Transmucosal Drugs Global Market Report 2025 – By Product Type (Tablets, Films, Liquid And Spray, Other Product Types), By Indication (Opioid Dependence, Nausea And Vomiting, Erectile Dysfunction, Neurological Disor...

Sugarcane Syrup Global Market Report 2025 – By Type (Pure Sugarcane Syrup, Mix Sugarcane Syrup), By Distribution Channel (Supermarkets And Hypermarkets, Convenience Stores, Online Retail Stores, Other Distribution Channe...

Oral Care Global Market Report 2025 – By Product Type (Toothpaste, Mouth Wash and Rinse, Teeth Whitening, Dental Floss, Tooth Brush, Orthodontic Wax), By Distribution Channel (Store-based, Non-Store-Based), By End User (...

Frequently Asked Questions

What is the definition of the Oral Hypoglycemic Agents market?

How will the Oral Hypoglycemic Agents market drivers and restraints affect the market dynamics? What forces will shape the Oral Hypoglycemic Agents industry going forward?

The market major growth driver - Rising Prevalence Of Type 2 Diabetes Driving Growth In The Market Due To Increasing Obesity And Demand For Effective Blood Sugar Management. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Oral Hypoglycemic Agents market?

The oral hypoglycemic agents market size has grown steadily in recent years. It will grow from $57.04 billion in 2024 to $59.57 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to the growing prevalence of type 2 diabetes, rising geriatric population, growing awareness of diabetes management, expansion of healthcare access in emerging markets, and the preference for oral over injectable therapies. The oral hypoglycemic agents market size is expected to see steady growth in the next few years. It will grow to " $72.09 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to rising demand for combination therapies, supportive government healthcare policies, increasing adoption of telemedicine for diabetes care, rising investment in research and development for diabetes treatments, and rising focus on personalized diabetes treatment. Major trends in the forecast period include the development of novel oral antidiabetics, the development of fixed-dose combinations, technological advancements in drug formulation, a focus on reducing drug side effects, and the integration of digital health tools for glucose monitoring. For further insights on this market, request a sample here

How is the Oral Hypoglycemic Agents market segmented?

The oral hypoglycemic agents market covered in this report is segmented –
1) By Product Type: Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Immunotherapy
2) By Administration Route: Oral Tablets, Oral Liquids, Extended-Release Formulations, Combination Therapy Formulations
3) By Patient Type: Type 2 Diabetes Mellitus Patients, Pre-diabetic Patients, Obese Or Overweight Patients, Patients with Multiple Comorbidities
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Nursing Homes and Long-Term Care Facilities
5) By End users: Hospitals, Clinics Subsegments:
1) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide
2) By Metformin: Immediate-Release Metformin, Extended-Release Metformin (XR), Combination Metformin
3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose
5) By Immunotherapy: Teplizumab, Alum-Formulated GAD (GAD-Alum), Diamyd, Anti-CD3 Monoclonal Antibodies For further insights on this market, request a sample here

Which region has the largest share of the Oral Hypoglycemic Agents market? What are the other regions covered in the report?

North America was the largest region in the oral hypoglycemic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral hypoglycemic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Oral Hypoglycemic Agents market?

What are the key trends in the Oral Hypoglycemic Agents market?

Major trends in this market include Development Of Advanced Oral Hypoglycemic Agents Driving Market Growth, With DPP-4 Inhibitors Gaining Traction. For further insights on this market, request a sample here.